Global Markets Direct’s, ‘Osteoarthritis – Pipeline Review, H2 2015′, provides an overview of the Osteoarthritis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Osteoarthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Osteoarthritis
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Osteoarthritis and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Osteoarthritis pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Osteoarthritis
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Osteoarthritis pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
Introduction 6
Osteoarthritis Overview 7
Therapeutics Development 8
Osteoarthritis - Therapeutics under Development by Companies 10
Osteoarthritis - Therapeutics under Investigation by Universities/Institutes 17
Osteoarthritis - Pipeline Products Glance 18
Osteoarthritis - Products under Development by Companies 21
Osteoarthritis - Products under Investigation by Universities/Institutes 28
Osteoarthritis - Companies Involved in Therapeutics Development 29
Osteoarthritis - Therapeutics Assessment 91
Drug Profiles 104
Osteoarthritis - Recent Pipeline Updates 248
Osteoarthritis - Dormant Projects 285
Osteoarthritis - Discontinued Products 293
Osteoarthritis - Product Development Milestones 295
Appendix 302

List of Tables

Number of Products under Development for Osteoarthritis, H2 2015 21
Number of Products under Development for Osteoarthritis - Comparative Analysis, H2 2015 22
Number of Products under Development by Companies, H2 2015 24
Number of Products under Development by Companies, H2 2015 (Contd..1) 25
Number of Products under Development by Companies, H2 2015 (Contd..2) 26
Number of Products under Development by Companies, H2 2015 (Contd..3) 27
Number of Products under Development by Companies, H2 2015 (Contd..4) 28
Number of Products under Development by Companies, H2 2015 (Contd..5) 29
Number of Products under Investigation by Universities/Institutes, H2 2015 30
Comparative Analysis by Late Stage Development, H2 2015 31
Comparative Analysis by Clinical Stage Development, H2 2015 32
Comparative Analysis by Early Stage Development, H2 2015 33
Products under Development by Companies, H2 2015 34
Products under Development by Companies, H2 2015 (Contd..1) 35
Products under Development by Companies, H2 2015 (Contd..2) 36
Products under Development by Companies, H2 2015 (Contd..3) 37
Products under Development by Companies, H2 2015 (Contd..4) 38
Products under Development by Companies, H2 2015 (Contd..5) 39
Products under Development by Companies, H2 2015 (Contd..6) 40
Products under Investigation by Universities/Institutes, H2 2015 41
Osteoarthritis - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015 42
Osteoarthritis - Pipeline by AbbVie Inc., H2 2015 43
Osteoarthritis - Pipeline by Abiogen Pharma S.p.A., H2 2015 44
Osteoarthritis - Pipeline by Addex Therapeutics Ltd, H2 2015 45
Osteoarthritis - Pipeline by Akari Therapeutics, Plc, H2 2015 46
Osteoarthritis - Pipeline by Ampio Pharmaceuticals, Inc., H2 2015 47
Osteoarthritis - Pipeline by Amura Holdings Limited, H2 2015 48
Osteoarthritis - Pipeline by Arcarios BV, H2 2015 49
Osteoarthritis - Pipeline by Asahi Kasei Pharma Corp., H2 2015 50
Osteoarthritis - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2015 51
Osteoarthritis - Pipeline by Astellas Pharma Inc., H2 2015 52
Osteoarthritis - Pipeline by Biopharm GmbH, H2 2015 53
Osteoarthritis - Pipeline by Can-Fite BioPharma Ltd., H2 2015 54
Osteoarthritis - Pipeline by Cara Therapeutics, Inc., H2 2015 55
Osteoarthritis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2015 56
Osteoarthritis - Pipeline by Cellceutix Corporation, H2 2015 57
Osteoarthritis - Pipeline by Cellular Biomedicine Group, Inc., H2 2015 58
Osteoarthritis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 59
Osteoarthritis - Pipeline by Dong-A ST Co., Ltd., H2 2015 60
Osteoarthritis - Pipeline by Eli Lilly and Company, H2 2015 61
Osteoarthritis - Pipeline by Evgen Pharma PLC, H2 2015 62
Osteoarthritis - Pipeline by Galapagos NV, H2 2015 63
Osteoarthritis - Pipeline by Genequine Biotherapeutics GmbH, H2 2015 64
Osteoarthritis - Pipeline by GlaxoSmithKline Plc, H2 2015 65
Osteoarthritis - Pipeline by IMMD Inc., H2 2015 66
Osteoarthritis - Pipeline by IntelliCell BioSciences Inc., H2 2015 67
Osteoarthritis - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015 68
Osteoarthritis - Pipeline by Jenrin Discovery, Inc., H2 2015 69
Osteoarthritis - Pipeline by K-Stemcell Co., Ltd., H2 2015 70
Osteoarthritis - Pipeline by Levolta Pharmaceuticals, Inc., H2 2015 71
Osteoarthritis - Pipeline by Medivir AB, H2 2015 72
Osteoarthritis - Pipeline by Merck KGaA, H2 2015 73
Osteoarthritis - Pipeline by Mesoblast Limited, H2 2015 74
Osteoarthritis - Pipeline by Mor Research Application Ltd, H2 2015 75
Osteoarthritis - Pipeline by NicOx S.A., H2 2015 76
Osteoarthritis - Pipeline by Nordic Bioscience A/S, H2 2015 77
Osteoarthritis - Pipeline by Novartis AG, H2 2015 78
Osteoarthritis - Pipeline by Ocata Therapeutics, Inc., H2 2015 79
Osteoarthritis - Pipeline by Omeros Corporation, H2 2015 80
Osteoarthritis - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 81
Osteoarthritis - Pipeline by OrthoCyte Corporation, H2 2015 82
Osteoarthritis - Pipeline by Osteologix Holdings Plc, H2 2015 83
Osteoarthritis - Pipeline by Pfizer Inc., H2 2015 84
Osteoarthritis - Pipeline by Pharmalink AB, H2 2015 85
Osteoarthritis - Pipeline by PolyNovo Limited, H2 2015 86
Osteoarthritis - Pipeline by Regeneus Ltd, H2 2015 87
Osteoarthritis - Pipeline by ReqMed Company, Ltd., H2 2015 88
Osteoarthritis - Pipeline by Rottapharm SpA, H2 2015 89
Osteoarthritis - Pipeline by Sanofi, H2 2015 90
Osteoarthritis - Pipeline by Seikagaku Corporation, H2 2015 91
Osteoarthritis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2015 92
Osteoarthritis - Pipeline by STELIS Biopharma Pvt. Ltd., H2 2015 93
Osteoarthritis - Pipeline by Stempeutics Research Private Limited, H2 2015 94
Osteoarthritis - Pipeline by Symic Biomedical, Inc., H2 2015 95
Osteoarthritis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 96
Osteoarthritis - Pipeline by TissueGene, Inc., H2 2015 97
Osteoarthritis - Pipeline by Upsher-Smith Laboratories, Inc., H2 2015 98
Osteoarthritis - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2015 99
Osteoarthritis - Pipeline by Yuhan Corporation, H2 2015 100
Osteoarthritis - Pipeline by Yungjin Pharm. Co., Ltd., H2 2015 101
Osteoarthritis - Pipeline by Zimmer Biomet Holdings, Inc., H2 2015 102
Osteoarthritis - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2015 103
Assessment by Monotherapy Products, H2 2015 104
Assessment by Combination Products, H2 2015 105
Number of Products by Stage and Target, H2 2015 107
Number of Products by Stage and Mechanism of Action, H2 2015 111
Number of Products by Stage and Route of Administration, H2 2015 114
Number of Products by Stage and Molecule Type, H2 2015 116
Osteoarthritis Therapeutics - Recent Pipeline Updates, H2 2015 261
Osteoarthritis - Dormant Projects, H2 2015 298
Osteoarthritis - Dormant Projects (Contd..1), H2 2015 299
Osteoarthritis - Dormant Projects (Contd..2), H2 2015 300
Osteoarthritis - Dormant Projects (Contd..3), H2 2015 301
Osteoarthritis - Dormant Projects (Contd..4), H2 2015 302
Osteoarthritis - Dormant Projects (Contd..5), H2 2015 303
Osteoarthritis - Dormant Projects (Contd..6), H2 2015 304
Osteoarthritis - Dormant Projects (Contd..7), H2 2015 305
Osteoarthritis - Discontinued Products, H2 2015 306
Osteoarthritis - Discontinued Products (Contd..1), H2 2015 307

List of Figures

Number of Products under Development for Osteoarthritis, H2 2015 21
Number of Products under Development for Osteoarthritis - Comparative Analysis, H2 2015 22
Number of Products under Development by Companies, H2 2015 23
Number of Products under Investigation by Universities/Institutes, H2 2015 30
Comparative Analysis by Late Stage Development, H2 2015 31
Comparative Analysis by Clinical Stage Development, H2 2015 32
Comparative Analysis by Early Stage Products, H2 2015 33
Assessment by Monotherapy Products, H2 2015 104
Assessment by Combination Products, H2 2015 105
Number of Products by Top 10 Targets, H2 2015 106
Number of Products by Stage and Top 10 Targets, H2 2015 106
Number of Products by Top 10 Mechanism of Actions, H2 2015 110
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 110
Number of Products by Top 10 Routes of Administration, H2 2015 113
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 113
Number of Products by Top 10 Molecule Types, H2 2015 115
Number of Products by Stage and Top 10 Molecule Types, H2 2015 115